Alzheimer's disease (AD) is a type of
neurodegenerative disease that is associated with the accumulation of
amyloid plaques. Increasing non-amyloidogenic processing and/or manipulating
amyloid precursor
protein signaling could reduce AD
amyloid pathology and
cognitive impairment.
D-penicillamine (D-Pen) is a water-soluble
metal chelator and can reduce the aggregation of
amyloid-β (Aβ) with metals in vitro. However, the potential mechanism of D-Pen for treating
neurodegenerative disorders remains unexplored. In here, a novel type of
chitosan-based
hydrogel to carry D-Pen was designed and the D-Pen-CS/β-
glycerophosphate hydrogel were characterized by scanning electron microscopy and HPLC. Behavior tests investigated the learning and memory levels of APP/PS1 mice treated through the D-Pen
hydrogel nasal delivery. In vivo and in vitro findings showed that nasal delivery of D-Pen-CS/β-GP
hydrogel had properly chelated
metal ions that reduced Aβ deposition. Furthermore, D-Pen mainly regulated A
disintegrin and
metalloprotease 10 (ADAM10) expression via
melatonin receptor 1 (MTNR1α) and the downstream PKA/ERK/CREB pathway. The present data demonstrated D-Pen significantly improved the cognitive ability of APP/PS1 mice and reduced Aβ generation through activating ADAM10 and accelerating non-amyloidogenic processing. Hence, these findings indicate the potential of D-Pen as a promising agent for treating AD.